BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BMRN • US09061G1013

58.13 USD
+0.98 (+1.71%)
At close: Feb 6, 2026
58.13 USD
0 (0%)
After Hours: 2/6/2026, 8:20:08 PM
Fundamental Rating

6

BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, BMRN could be worth investigating further for value and quality investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year BMRN was profitable.
  • In the past year BMRN had a positive cash flow from operations.
  • Of the past 5 years BMRN 4 years were profitable.
  • BMRN had a positive operating cash flow in each of the past 5 years.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

  • BMRN's Return On Assets of 6.83% is amongst the best of the industry. BMRN outperforms 92.75% of its industry peers.
  • BMRN's Return On Equity of 8.59% is amongst the best of the industry. BMRN outperforms 92.18% of its industry peers.
  • BMRN has a better Return On Invested Capital (7.69%) than 94.08% of its industry peers.
  • BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 18.12%.
  • The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROIC 7.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • Looking at the Profit Margin, with a value of 16.82%, BMRN belongs to the top of the industry, outperforming 92.75% of the companies in the same industry.
  • With an excellent Operating Margin value of 20.21%, BMRN belongs to the best of the industry, outperforming 94.66% of the companies in the same industry.
  • BMRN has a better Gross Margin (81.32%) than 85.31% of its industry peers.
  • BMRN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
  • Compared to 1 year ago, BMRN has more shares outstanding
  • Compared to 5 years ago, BMRN has more shares outstanding
  • The debt/assets ratio for BMRN has been reduced compared to a year ago.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • BMRN has an Altman-Z score of 5.42. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BMRN (5.42) is better than 75.00% of its industry peers.
  • BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
  • BMRN's Debt to FCF ratio of 0.72 is amongst the best of the industry. BMRN outperforms 94.47% of its industry peers.
  • A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.10, BMRN is not doing good in the industry: 62.40% of the companies in the same industry are doing better.
  • Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Altman-Z 5.42
ROIC/WACC0.92
WACC8.38%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • BMRN has a Current ratio of 4.83. This is comparable to the rest of the industry: BMRN outperforms 55.73% of its industry peers.
  • BMRN has a Quick Ratio of 3.10. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.10, BMRN is not doing good in the industry: 60.88% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 4.83
Quick Ratio 3.1
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.00% over the past year.
  • The Revenue has grown by 12.39% in the past year. This is quite good.
  • Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%

3.2 Future

  • Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
  • Based on estimates for the next years, BMRN will show a small growth in Revenue. The Revenue will grow by 7.22% on average per year.
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 21.85, the valuation of BMRN can be described as rather expensive.
  • Based on the Price/Earnings ratio, BMRN is valued cheaply inside the industry as 94.66% of the companies are valued more expensively.
  • BMRN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.92, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 12.52, the valuation of BMRN can be described as correct.
  • BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 97.52% of the companies in the same industry.
  • BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.78.
Industry RankSector Rank
PE 21.85
Fwd PE 12.52
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 95.42% of the companies listed in the same industry.
  • 97.33% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.52
EV/EBITDA 13.94
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of BMRN may justify a higher PE ratio.
  • A more expensive valuation may be justified as BMRN's earnings are expected to grow with 35.45% in the coming years.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y44.96%
EPS Next 3Y35.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (2/6/2026, 8:20:08 PM)

After market: 58.13 0 (0%)

58.13

+0.98 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27
Earnings (Next)02-25
Inst Owners97.82%
Inst Owner Change-2.77%
Ins Owners0.64%
Ins Owner Change-0.95%
Market Cap11.17B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target93.43 (60.73%)
Short Float %3.88%
Short Ratio2.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)1.47%
PT rev (3m)-2.38%
EPS NQ rev (1m)-29.03%
EPS NQ rev (3m)-25.47%
EPS NY rev (1m)-5.52%
EPS NY rev (3m)-16.53%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 21.85
Fwd PE 12.52
P/S 3.61
P/FCF 13.52
P/OCF 12.22
P/B 1.84
P/tB 1.98
EV/EBITDA 13.94
EPS(TTM)2.66
EY4.58%
EPS(NY)4.64
Fwd EY7.99%
FCF(TTM)4.3
FCFY7.39%
OCF(TTM)4.76
OCFY8.18%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.77
PEG (5Y)N/A
Graham Number43.44
Profitability
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROCE 9.17%
ROIC 7.69%
ROICexc 9.82%
ROICexgc 10.68%
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
FCFM 26.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Debt/EBITDA 0.84
Cap/Depr 106.6%
Cap/Sales 2.85%
Interest Coverage 85.91
Cash Conversion 129.08%
Profit Quality 158.68%
Current Ratio 4.83
Quick Ratio 3.1
Altman-Z 5.42
F-Score8
WACC8.38%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%

BIOMARIN PHARMACEUTICAL INC / BMRN FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to BMRN.


What is the valuation status for BMRN stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.


Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?

BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.


What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.


What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 28.21% in the next year.